AKT1 and endometrioid tumor: Both endometrioid and non-endometrioid tumor histologies harbor mutations that upregulate the phosphoinositide-3 kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway [18].